These data suggest that an initial SC-Ad-Spike vaccination generates anti-Spike antibodies and CD8+ T cells that can prevent subsequent infection with the VSV-Spike-mIFNß boost (which relies on Spike-ACE2 receptor binding), thereby inhibiting the generation of anti-VSV CD8+ T-cell responses in this regimen. Here, CD8A is linked to infection.